Compounded GLP-1 drops or tablets vs injections: do the oral versions work?

Short answer: probably not. Compounded “GLP‑1” drops or tablets are unreliable and likely far less effective (and less safe) than FDA‑approved formulations — especially the injectable GLP‑1 receptor agonists. The only FDA‑approved oral GLP‑1 is semaglutide (brand name Rybelsus) and it works because of a specific tablet formulation/absorption enhancer; random compounded oral peptides do not have the same proven absorption or quality controls.

Key points

• How GLP‑1 drugs work and why formulation matters

  • GLP‑1 peptides are fragile and are normally broken down in the stomach/intestine. Approved oral semaglutide (Rybelsus) includes an absorption enhancer (SNAC) and a precisely manufactured tablet to allow enough drug to get into the bloodstream.
  • Injectables (Ozempic, Wegovy, Trulicity, Mounjaro/Zepbound) bypass the gut and deliver reliable, predictable doses — which is why they have the strongest evidence for blood‑sugar control and weight loss.

• Why compounded oral drops/tablets are risky and often ineffective

  • No regulatory approval or clinical trials proving they work or are safe in that formulation.
  • Variable/unknown bioavailability: oral peptide absorption without a proven enhancer is usually negligible.
  • Risk of inconsistent dosing, contamination, incorrect storage/stability, and unknown source of peptide.
  • Potential legal/regulatory issues and lack of manufacturer support (no patient assistance, no pharmacovigilance).

• Evidence/practical differences

  • Rybelsus (oral semaglutide) is the only proven oral GLP‑1. It has clinical trial data showing meaningful glucose lowering and modest weight loss when taken exactly as instructed (fasting, very little water, wait ~30 minutes before eating or other meds).
  • Injectable GLP‑1s (Ozempic/Wegovy — semaglutide; Trulicity — dulaglutide; Mounjaro/Zepbound — tirzepatide) generally produce larger and more reliable effects, especially for weight loss at higher doses.

• Safety considerations

  • Class side effects: nausea, vomiting, constipation, decreased appetite, possible pancreatitis, gallbladder disease, and (in animals) thyroid C‑cell tumors — avoid in patients with medullary thyroid carcinoma or MEN2.
  • Any compounded product also risks contamination and lack of post‑market safety monitoring.

What I recommend

• Avoid compounded GLP‑1 drops or tablets. They’re unproven and potentially unsafe.
• If you want an oral option, discuss Rybelsus (oral semaglutide) with your clinician — it’s FDA‑approved and has known dosing rules and evidence.
• If you want maximum effectiveness for weight loss or diabetes control, consider the injectables (Ozempic/Wegovy — semaglutide; Mounjaro/Zepbound — tirzepatide; Trulicity — dulaglutide) and talk with your prescriber about which fits your goals and medical history.
• If cost or access is the issue, ask your clinician/pharmacy about manufacturer savings programs, patient assistance, or approved alternatives rather than turning to compounding.

If you want, tell me whether your goal is diabetes control or weight loss, any medical problems (thyroid cancer history, pancreatitis), and whether insurance/cost is a barrier — I can suggest specific medication options and practical next steps.